Gosselies, Belgium (PRWEB) February 10, 2016
Dr. Philippe Monteyne is appointed as partner of Fund+ NV and Dr. Jean-Paul Prieels as an independent non-executive director designated by SFPI.
Philppe Monteyne MD, PhD is VC Partner with Fund+ NV in Belgium, and visiting Professor of Neurosciences at UCL, Catholic University of Louvain in Belgium. From Oct 2012 until end 2014, he was Vice President R&D France, Sanofi, in Paris area, reporting directly to the President Global R&D. Prior to that (2010-2012), Philippe was the Senior Vice President - Head of Development and CMO, GSK Rare Diseases. From 1998 to 2010, he held various executive positions at GlaxoSmithKline, including Head of Global Vaccine Development.
Jean-Paul Prieels PhD is an industry expert in pharmaceutical development. He held various executive positions at GlaxoSmithKline Biologicals where he started in 1987 and has been instrumental in developing several marketed vaccines. He retired from GSK as Senior Vice President Research and Development in early 2011 and is currently a board member of several biotech companies. He is designated by SFPI (Société Fédérale de Participations et d'Investissement, Belgium) to seat on the Board of directors of Euroscreen.
Dr. Monteyne: "At Fund+, we are delighted to join Euroscreen as shareholders and to actively contribute to its success through this role at the Board level. Euroscreen is a highly promising clinical stage company, which fits perfectly with our policy to develop a leadership position in the Life Sciences sector in Belgium."
Dr. Prieels: "I am thrilled to be able to be involved in the development of Euroscreen’s promising pipeline and am grateful to SFPI fort this board membership."
"We are very pleased and proud that Philippe and Jean-Paul have agreed to become members of the Euroscreen Board of Directors. Their proven track record of drug development and accomplishments will bring a lot of experience and expertise in our Board of Directors,” commented Jean Combalbert, CEO of Euroscreen.
Euroscreen is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for unmet medical needs. Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules. Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health Disorders. In addition, Euroscreen advances other small molecules (preclinical stage) targeting G-Protein Coupled Receptors of interest in multiple therapeutic areas such as neurodegenerative diseases and inflammation. Euroscreen is backed by leading investors, including Vesalius Biocapital, SFPI-FPIM, SRIW, Fund+ and BNP Paribas Fortis Private Equity. http://www.euroscreen.com